The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises:

##STR00001## or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R.sup.1 and R.sup.3 each independently represent, at each occurrence when used herein, H or C.sub.1 to C.sub.5 alkyl; R.sup.2 represents halo; R.sup.4 and R.sup.5 each independently represent H; R.sup.6 represents —C(O)OR.sup.9; X represents CH.sub.2, O or S; R.sup.9 represents H or C.sub.1 to C.sub.5 alkyl; and, m is an integer from 1 to 6 inclusive.

Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises:

##STR00001## or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R.sup.1 and R.sup.3 each independently represent, at each occurrence when used herein, H or C.sub.1 to C.sub.5 alkyl; R.sup.2 represents halo; R.sup.4 and R.sup.5 each independently represent H; R.sup.6 represents —C(O)OR.sup.9; X represents CH.sub.2, O or S; R.sup.9 represents H or C.sub.1 to C.sub.5 alkyl; and, m is an integer from 1 to 6 inclusive.

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

##STR00001##

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

##STR00001##

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

The present invention provides a compound having the structure:

##STR00001##

or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.

Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises:

##STR00001##

or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity,
wherein:
R.sup.1 and R.sup.3 each independently represent, at each occurrence when used herein, H or C.sub.1 to C.sub.5 alkyl;
R.sup.2 represents halo;
R.sup.4 and R.sup.5 each independently represent H;
R.sup.6 represents C(O)OR.sup.9;
X represents CH.sub.2, O or S;
R.sup.9 represents H or C.sub.1 to C.sub.5 alkyl; and,
m is an integer from 1 to 6 inclusive.